AnPac Bio-Medical Science Co

Anpac Bio-Medical Science Co., Ltd., is a biotechnology company. It engages in marketing and selling multi-cancer screening and detection test that uses patented cancer differentiation analysis, or CDA, technology and proprietary cancer-detection device or CDA device. The company was founded by Chris Chang Yu and He Yu in 2010 and is headquartered in Lishui, China.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresh2 Group Ltd. is a biotechnology company. It engages in marketing and selling multi-cancer screening and detection test that uses patented cancer differentiation analysis, or CDA, technology and proprietary cancer-detection device or CDA device. The company was founded by Chris Chang Yu and He Yu in January 2010 and is headquartered in Lishui, China.

SAN JOSE, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced strong demand for its cancer screening tests and set a record in paid test volume in the third quarter. With a strong fourth quarter already underway, the Company forecasts a revenue growth of approximately 100% in 2020 over 2019, with a revenue range of US$3 million (~ RMB20 million) to US$3.3 million (~ RMB22 million). For 2019, the Company had a revenue of US$1.6 million (~ RMB10.9 million) (using a current US$ to RMB exchange ratio of ~ 6.6). We expect the strong momentum of YoY revenue growth due to market demand and customers accepting AnPac Bio's novel cancer screening technology with multiple advantages (named cancer differentiation analysis (CDA) technology)) to continue into 2021. The Company plans to release its full year 2020 audited financial report in early March 2021.

AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020

SAN JOSE, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States announced today that the Company has completed an FDA EUA- SARS-CoV-2 (COVID-19) antibody test verification in its San Jose, California lab in November 2020 for the Roche Elecsys Anti Sars-COV-2 test, and is now capable of entering into the commercial testing stage. The Company also announced that COVID-19 antibody test equipment has also completed installation in its Philadelphia lab.

AnPac Bio US Completes COVID-19 Antibody Test Verification and Approved to Begin Commercial Testing

SAN JOSE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States announced today that the Company's investee company in China, Jiangsu AnPac Health Management Co., Ltd. (“Jiangsu AnPac”) (in which Jiangsu AnPac and AnPac Bio are a Joint Venture with the Company owning 15% equity interest), qualified for COVID-19 nucleic acid tests in the first half of 2020 and received certification from the regulatory authority on October 17, 2020 for COVID-19 nucleic acid tests in Jiangsu AnPac's medical lab in the City of WuXi, Jiangsu Province, China.  Jiangsu AnPac has begun to receive samples for paid COVID-19 nucleic acid tests.  Recently, AnPac Bio and Jiangsu AnPac have signed an agreement to develop and qualify new COVID-19 test technologies and products, and carry out evaluations at Jiangsu AnPac's medical lab. 

AnPac Bio's Investee Company in China Received COVID-19 Nucleic Acid Test Certification and Began Volume Tests and Collaborations with AnPac Bio

SAN JOSE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has completed over 200,000 cancer detection tests as of September 30, 2020 using its biophysics based cancer screening technology, Cancer Differentiation Analysis (“CDA”).The CDA technology allows cancer screening for close to 60 types of cancer, including certain cancer types such as esophageal cancer and brain tumors which do not yet have other more-established blood based testing methods.

Anpac Bio Completes Over 200,000 Biophysics Based Cancer Detection Tests, With Data Covering Close to 60 Types of Cancer

SAN JOSE, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today that in recognition of its successes in leading edge life science innovations and advancements and in support of its R&D and product commercialization efforts, AnPac Bio has obtained three grants and one rental award from various local authorities in China with a portion of the funding subject to milestone achievements. In total, these grants and award reached approximately US$8 million. Grant and award payments or benefits are expected to be received over a few years starting from this quarter and will help AnPac Bio fund R&D and new product commercialization.

AnPac Bio to Receive Up To USD $8 Million Dollar Grants and Award for R&D, Product Commercialization, and Milestone Achievements

SAN JOSE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today that the Company has entered into an agreement with Keystone Capital Partners (“Keystone”) for a preferred stock investment of US$7.0 Million. Additional details on the transaction are outlined in the accompanying Registration Statement filed on September 30, 2020 (File No. 333‐249170).

AnPac Bio Announces Equity Investment from Keystone Capital Partners for up to $7 Million

AnPac Bio-Medical Science Co., Ltd (ANPC) CEO Chris Yu on Q2 2020 Results - Earnings Call Transcript

SAN JOSE, Calif., Sept.  10, 2020  (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its financial results for the six months ended June 30, 2020.

AnPac Bio Reports First Six Months of 2020 Financial Results

Ault Global Holdings

I-Mab

Companies in the news are: IMAB, LMPX, DPW, ANPC

Company News for Sep 8, 2020

AnPac Bio-Medical Science (ANPC) saw an increase to ANPC stock on Friday following positive results from a clinical trial.
The post Why AnPac Bio-Medical Science Stock Is Soaring 7% Today appeared first on InvestorPlace.

Why AnPac Bio-Medical Science Stock Is Soaring 7% Today

SAN JOSE, Calif., Sept.  04, 2020  (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today positive results from a successfully completed a multi-year lung cancer prognosis and recurrence study in collaboration with a major hospital in China. The clinical study began in 2014, with the enrollment and completed all follow-up and testing in 2020. Approximately 1,000 confirmed lung cancer patients were tested in the clinical study using AnPac Bio’s cancer differentiation analysis (CDA) technology for prognosis and recurrence utility evaluations throughout initial diagnosis, surgery, chemotherapy and other treatments, and remission (for recurrence monitoring).

AnPac Bio Announces Positive Results from a Multi-Year Lung Cancer Prognosis and Recurrence Clinical Study

Earnings Call Scheduled for 8:00 am ET on September 10, 2020 Earnings Call Scheduled for 8:00 am ET on September 10, 2020

AnPac Bio to Report its First Six Months 2020 Financial Results on Thursday, September 10, 2020

SAN JOSE, Calif., Aug.  24, 2020  (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States announced today that the company received a certificate of registration this month under the U.S.  Clinical Laboratory Improvement Amendments  of 1988, or CLIA, for its approximately 7,000 square foot lab in Philadelphia, Pennsylvania.  The AnPac Bio Philadelphia lab is dedicated to cancer differentiation analysis (CDA) liquid biopsy research as well as various other commercial diagnostic testing.

AnPac Bio Philadelphia Lab Gains U.S. CLIA Lab Certification

SAN JOSE, Calif., Aug.  11, 2020  (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today that the Company has commenced operations of its new Philadelphia lab, with the completion of its facility renovation and first phase equipment installation in July 2020. A Roche Cobas e411 machine, a diagnostic analyzer, which has received the FDA’s Emergency Use Authorization for performing COVID-19 anti-body tests, is among the Laboratory’s first phase equipment.

AnPac Bio Opens US Philadelphia Lab Operations

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) shares surged higher on Friday after the company reaffirmed its status as a COVID-19 stock.

Investors Cheer AnPac Bio’s Coronavirus Developments

SAN JOSE, Calif., Aug.  07, 2020  (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States announced today that the Company has been validating the approved COVID-19 antibody test, which has received the FDA’s Emergency Use Authorization, for commercial use in its San Jose, California lab since the second quarter of 2020, with expected validation completion in the second half of 2020.

AnPac Bio Validating Approved COVID-19 Antibody Test

SAN JOSE, Calif., Aug.  04, 2020  (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today preliminary results from two prospective studies demonstrated that AnPac Bio’s Cancer Differentiation Analysis (CDA) based tests have the ability to assess the risks of cancer occurrence. 

AnPac Bio Announces Preliminary Results From Prospective Trials Indicating Early-Stage Cancer Screening Effectiveness

SAN JOSE, Calif., July  29, 2020  (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today it had completed over 180,000 Cancer Differentiation Analysis (“CDA”) based tests as of July 15, 2020.

AnPac Bio Completes Over 180,000 CDA-Based Cancer Risk Assessment Tests

SAN JOSE, Calif., July  13, 2020  (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, pre-announced certain results from the quarter ending 6/30/20. The Company performed 6,500 paid tests in June 2020, which was almost 50% higher than the average monthly paid tests in 2019.  Based on unaudited numbers for the first half of the year in 2020 through 6/30/20, revenue was slightly higher compared to the same period in 2019, while the average selling price (ASP) increased as well over 2019.  AnPac Bio plans to file the 1st half year results on August 28, 2020.  

AnPac Bio Completed 1st Half Year with Increased ASP and Revenue

SAN JOSE, Calif., June  26, 2020  (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that Frost & Sullivan has recently ranked AnPac Bio number three globally and number one in China in liquid biopsy for both clinical and commercial samples in the year of 2019 in cancer screening. That includes all next generation early cancer screening technologies, including CTC’s (circulating tumor cells), ct-DNA (circulating tumor DNA), exosomes, CDA (cancer differentiation analysis), mRNA (microRNAs), and other emerging technologies. AnPac Bio’s proprietary CDA platform utilizes combination tests which can both screen for overall cancer risk as well as provide cancer location information.

AnPac Bio Ranked #3 in Liquid Biopsy Clinical Samples Globally by Frost & Sullivan While Retaining #1 Position and Widening its Lead in China in Cancer Screening

SAN JOSE, Calif., June  22, 2020  (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that  the Company launched a new immunology test product line in China during the week of June 15, 2020.  This immunology test product line consists of multiple government-approved immunology related tests, and relies on AnPac Bio’s novel multi-level, multi-parameter scientific approach and expertise along with our proprietary algorithms.

AnPac Bio Launches New Immunology Test Product Line

The announcement that AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) has entered into a three-year strategic cancer screening collaboration contract with Beijing Yuan Jian Health Management in China lit a fire under the shares Friday morning.

News for AnPac Bio-Medical Science Co Stock (ANPC)